E
RYTM icon

Ergoteles’s Rhythm Pharmaceuticals RYTM Stock Holding History

Ergoteles’s Portfolio RYTM Stock Details RYTM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-11,563
Closed -$206K – 1450
2023
Q1 		$206K Buy
+11,563
New +$290K 0.01% 1002
2022
Q3 		– Sell
-212,800
Closed -$883K – 1927
2022
Q2 		$883K Buy
+212,800
New +$1.16M 0.03% 591

Other funds holding RYTM

Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return

Ergoteles's RYTM Position: Q2 2023 in Review

Ergoteles sold out of Rhythm Pharmaceuticals (RYTM) in Q2 2023, closing a stake of 11,563 shares — an estimated $206K sold.

Ergoteles first reported a position in RYTM in Q2 2022 and held it in 2 quarters. The position peaked at $883K in Q2 2022. 116 funds tracked by Wall St. Rank hold RYTM as of Q2 2023.

  • Ergoteles reported no remaining Rhythm Pharmaceuticals position as of Q2 2023 after selling out during the quarter.
  • Ergoteles sold 11,563 Rhythm Pharmaceuticals shares in Q2 2023, an estimated $206K.
  • Ergoteles first reported a position in Rhythm Pharmaceuticals in Q2 2022 and held it in 2 quarters.
  • Ergoteles's Rhythm Pharmaceuticals position peaked at $883K in Q2 2022.
  • 116 funds tracked by Wall St. Rank held Rhythm Pharmaceuticals as of Q2 2023.

Based on Ergoteles's 13F filing for Q2 2023, filed 14 Aug 2023.